NEW YORK, October 19, 2017 /PRNewswire/ --
If you want a Stock Review on CHRS, EXEL, GERN, or GRFS then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. Investor's Business Daily reported that 35 years after the first FDA-approved biotech drug, the Biotech industry is rolling out innovations at a breakneck pace.
Redwood City, California headquartered Coherus Biosciences Inc.'s stock finished Wednesday's session 1.09% higher at $13.85. A total volume of 575,914 shares was traded, which was above their three months average volume of 504,880 shares. The Company's shares have advanced 7.78% in the past month and 1.09% over the previous three months. The stock is trading above its 50-day moving average by 4.43%. Furthermore, shares of Coherus Biosciences, which focuses on developing and commercializing biosimilar products worldwide, have a Relative Strength Index (RSI) of 53.42. See our free and comprehensive research report on CHRS at:
Shares in South San Francisco, California headquartered Exelixis Inc. ended at $27.53, down 2.72% from the last trading session. The stock recorded a trading volume of 5.06 million shares, which was above its three months average volume of 3.86 million shares. The Company's shares have gained 2.00% in the previous three months and 84.64% on an YTD basis. The stock is trading 3.89% above its 50-day moving average and 20.22% above its 200-day moving average. Moreover, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 57.84.
On October 16th, 2017, Exelixis announced that the US Food and Drug Administration (FDA) has determined the Company's supplemental New Drug Application for CABOMETYX® (cabozantinib) for patients with previously untreated advanced renal cell carcinoma to be sufficiently complete to permit a substantive review. The FDA granted Priority Review of the filing and assigned a Prescription Drug User Fee Act action date of February 15th, 2018.
On October 17th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $33 a share to $39 a share. EXEL free research report is just a click away at:
Menlo Park, California-based Geron Corp.'s stock ended yesterday's session 0.48% lower at $2.08 with a total trading volume of 423,240 shares. The Company's shares have advanced 0.48% on an YTD basis. The stock is trading 2.78% below its 50-day moving average. Additionally, shares of Geron, which operates as a biopharmaceutical company, have an RSI of 41.59. Sign up for your complimentary report on GERN at:
On Wednesday, shares in Barcelona, Spain headquartered Grifols S.A. recorded a trading volume of 449,140 shares. The stock finished 0.05% lower at $21.50. The Company's shares have advanced 3.46% in the last one month, 2.77% in the previous three months, and 33.79% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.79% and 8.63%, respectively. Furthermore, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 57.47. Register for free on DailyStockTracker.com and download the latest research report on GRFS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All